Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Gardasil in Healthy Subjects Aged 9 to 13 Years in Malaysia
2019-003135-36Phase 3
- Sponsor
- Sanofi
- Start
- Oct 2019
- Modality
- Vaccines & Immunotherapeutics, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of qHPV vaccine and CYD dengue vaccine in dengue fever and human papillomavirus infection (2 arms), sponsored by Sanofi. Primary endpoints: HPV antibody geometric mean titers and HPV seroconversion rate.
02
Drugs
qHPV vaccineCYD dengue vaccine
03
Conditions
dengue feverhuman papillomavirus infection
Beyond the preview
Go deeper on 2019-003135-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003135-36.